Development of a Classifier for Metabolic Subtypes of Nasopharyngeal Carcinoma to Guide Personalized Immunotherapy Strategies: Biomarker Analysis of the Phase III CONTINUUM and DIPPER Trials - PubMed
5 days ago
- #immunotherapy
- #biomarker
- #nasopharyngeal carcinoma
- Development of a classifier for metabolic subtypes of nasopharyngeal carcinoma (NPC) to guide personalized immunotherapy strategies.
- Analysis based on data from the phase III CONTINUUM and DIPPER randomized clinical trials involving 407 patients.
- Three metabolic subtypes (MS1, MS2, MS3) identified with distinct tumor-intrinsic and immune features.
- MS1 subtype showed significant improvement in 3-year event-free survival (EFS) with anti-PD-1 plus chemoradiotherapy (CRT) versus CRT alone (90.2% vs 69.6%).
- MS2 and MS3 subtypes derived no significant survival benefit from immunotherapy.
- Metabolic subtypes preserved in validation cohort with consistent prognostic and predictive value.
- Pooled analysis demonstrated significant interaction between metabolic subtypes and treatment effect (Pinteraction = 0.0074).
- Novel molecular classification offers a predictive biomarker for personalized treatment in locoregionally advanced NPC.